9/27/04

104 1,pw

/	018	
PE	SEP 2 4 2004	,
(F	PADEMARKOR	

Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/769,157
Filing Date	1/29/2004
First Named Inventor	Joshua D. Rabinowitz
Art Unit	Not yet known
Examiner Name	To be assigned
Attorney Docket Number	00037.09CON

		ENCLOSU	IRES (check all that apply)	
Fee Transmittal	l Form	Drawing(s	s)		After Allowance communication to Group
Fee Atta	ached	Licensing	-related Papers		Appeal Communication to Board of Appeals and Interferences
Amendment / F	Reply	Petition			Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
After F	Final		o Convert a al Application		Proprietary Information
. Affidav	vits/declaration(s)		Attorney, Revocation f Correspondence		Status Letter
Extension of Ti	ime Request	Terminal	Disclaimer	X	Other Enclosure(s) (please identify below):
Express Aband	donment Request	Request	for Refund		
Information Disclosure Statement		CD, Number of CD(s)			
Certified Copy Document(s)	of Priority	Remarks		ll	
Response to N Incomplete Ap	•	Info. Discl. Statemetn (2 pp.) Form 1449 (3 copies, 8 pages each)			
	onse to Missing Parts 37 CFR 1.52 or 1.53	Copy of Arefe Return Postcard	rences / 8/		
	SIGNATUR	RE OF APPLICA	NT, ATTORNEY, OR AGEN	T	
	ALEXZA MDC, 1001 Elaine C. Stracker, P		ircle, Palo Alto, CA 9430 3 phone (650)-687-3905		Customer Number 37485
Signature	Hun	O She	ch		
Date	SEP. 2	4 2004			
		100			

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the

Typed or printed name	Elaine C. Stracker			
Signature	Their (Strake	Date	SEP. 24 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS PAPER AND THE DOCUMENTS REFERRED AS BEING ATTACHED OR ENCLOSED HEREWITH ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL OFFICE ON AS EXPRESS MAIL ADDRESSED TO: MAIL STOP AMENDMENT COMMISSIONER FOR

PATENTS, PO BOX 1450, ALEXANDRIA, VA 22313-1450

Efaine C. Stracker

PATENT

Attorney's Docket No.: 00037.09CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Rabinowitz et al.

Serial No.:

10/769,157

Filed:

1/29/2004

Title

DELIVERY OF ALPRAZOLAM, ESTAZOLAM, MIDAZOLAM OR

TRIAZOLAM THROUGH AN INHALATION ROUTE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with their continuing duty of disclosure under 37 CFR §§ §1.97, 1.98 and 1.56, Applicants hereby submit for consideration in the above-identified application the enclosed references. The Information Disclosure statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

For the convenience of the Examiner, the references are listed on a PTO Form 1449 (attached) and copies thereof are enclosed. Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines than an extension and/or other relief is required, Applicants petition for any required relief including any extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 502731**. Please direct all correspondence to the following customer number.

Respectfully submitted,

	SEP.	2	4	2004
Date:			•	

Elaine C. Stracker J.D., Ph.D., Reg. 43,166

Alexza Molecular Delivery Corporation 1001 East Meadow Circle Palo Alto, CA 94303

TEL: (650) 687-3905 FAX: (650) 687-3999 Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00037.09CON

Application Number: 10/769,157

Applicant:

Joshua D. RABINOWITZ et al.

Filing Date: 01/29/2004

Group Art Unit: Not Yet Known

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	02/02/1971	3,560,607	Hartley et al.			
	2.	05/27/1980	Re. 30,285	Babington			
	3.	10/21/1980	4,229,447	Porter			
	4.	04/02/1985	4,508,726	Coleman			
	5.	05/13/1986	4,588,721	Mahan			
	6.	07/28/1987	4,683,231	Glassman			
	7.	09/05/1989	4,863,720	Burghart et al.			
	8.	01/23/1990	4,895,719	Radhakrishnun et al.			
	9.	09/17/1991	5,049,389	Radhakrishnun			
	10.	03/31/1992	5,099,861	Clearman et al.			
	11.	11/24/1992	5,166,202	Schweizer			
	12.	08/31/1993	5,240,922	O'Neill			
	13.	02/14/1995	5,388,574	Ingebrethsen			
	14.	10/10/1995	5,457,100	Daniel			
	15.	08/06/1996	5,543,434	Weg		•	
	16.	08/13/1996	5,544,646	Lloyd et al.			
	17.	08/12/1997	5,655,523	Hodson et al.			
	18.	12/09/1997	5,694,919	Rubsamen et al.		,	
	19.	04/07/1998	5,735,263	Rubsamen et al.			
	20.	04/14/1998	5,738,865	Baichwal et al.			
	21.	06/02/1998	5,758,637	Ivri et al.			
	22.	06/16/1998	5,767,117	Moskowitz			
-	23.	06/29/1999	5,915,378	Lloyd et al.			
,	24.	08/10/1999	5,934,272	Lloyd et al.	<u> </u>		
	25.	09/28/1999	5,957,124	Lloyd et al.			
	26.	10/05/1999	5,960,792	Lloyd et al.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-144	Form PTO-1449		Docket Number: 00037.09CO	N Application Number: 10/769,157
1	TION DISCLOS IN AN APPLICA	SURE CITATION ATION	Applicant: Joshua D.	. RABINOWITZ et al.
	(Use several sheets if ne	ecessary)	Filing Date: 01/29/2004	Group Art Unit: Not Yet Known
	144/20/4000	5 202 205		
27.		5,993,805	Sutton et al.	
28.	03/28/2000	6,041,777	Faithfull et al.	
29.	04/11/2000	6,048,857	Ellinwood, Jr. et al.	
30.	04/18/2000	6,051,566	Bianco	
31.	06/20/2000	Re. 36,744	Goldberg	
32.	08/01/2000	6,095,153	Kessler et al.	
33.	08/15/2000	6,102,036	Slutsky et al.	
34.	10/17/2000	6,133,327	Kimura et al.	
. 35.	10/31/2000	6,140,323	Ellinwood, Jr. et al.	
36.	06/05/2001	6,241,969	Saidi et al.	
37.	07/03/2001	6,255,334	Sands	
38.	01/14/2003	6,506,762	Horvath et al.	
39.	02/04/2003	6,514,482	Bartus et al.	
40.	07/15/2003	6,591,839	Meyer et al.	
41.	09/06/2001	US 2001/0020147	Staniforth et al.	
42.	03/28/2002	US 2002/0037828	Wilson et al.	
43.	05/16/2002	US 2002/0058009	Bartus et al.	
44.	07/04/2002	US 2002/0086852	Cantor	
45.	08/22/2002	US 2002/0112723	Schuster et al.	
46.	11/28/2002	US 2002/0176841	Barker et al.	
47.	01/02/2003	US 2003/0004142	Prior et al.	
48.	02/13/2003	US2003/0032638	Kim et al.	
	·· I-·· · · · · · · · · · · · · · · · ·	10146086	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·
RELA'	TED ALEXZA N	MOLECULAR DELI	VERY CORPORATION	PATENT DOCUMENTS
49.	08/04/2003	10/633,876	Hale et al.	
50.	08/04/2003	10/633,877	Hale et al.	
51.	12/30/2003	10/749,537	Rabinowitz et al.	
52.	12/30/2003	10/749,539	Rabinowitz et al.	
53.	01/27/2004	10/766,149	Rabinowitz et al.	
54.	01/27/2004	10/766,279	Rabinowitz et al.	
EXAMINER:			DATE CONSIDEREI	D:
EXAMINER: Is	nitial if citation consid	ered, whether or not the cita	ation conforms with MPEP 609. Don next communication to applicant.	raw a line through the citation if not in
PTO/SB/ 08 (2-92)		ade a copy of this form with		fice; U.S. DEPARTMENT OF COMMERC
\				,

Form P	Form PTO-1449			Docket Number: 00037.09CON Application Number: 10/769,157		
INF		ATION DISCLOS IN AN APPLICA	SURE CITATION ATION	Applicant: Joshua D. RABINOWITZ et al.		
		(Use several sheets if n	ecessary)	Filing Date: 01/29/2004 Group Art Unit: Not Yet Known		
			10896954			
			10437643			
	55.	01/27/2004	10/766,566	Rabinowitz et al.		
	56.	01/27/2004	10/766,574	Rabinowitz et al.		
	57.	01/27/2004	10/766,634	Rabinowitz et al.		
	58.	01/27/2004	10/766,647	Rabinowitz et al.		
	59.	01/28/2004	10/767,115	Rabinowitz et al.		
	60.	01/29/2004	10/768,205	Rabinowitz et al.		
	61.	01/29/2004	10/768,220	Rabinowitz et al.		
	62.	01/29/2004	10/768,281	Rabinowitz et al.		
	63.	01/29/2004	10/768,293	Rabinowitz et al.		
	64.	01/30/2004	10/769,046	Rabinowitz et al.		
	65.	01/30/2004	10/769,051	Rabinowitz et al.		
	66.	01/29/2004	10/769,197	Rabinowitz et al.		
	67.	02/09/2004	10/775,583	Rabinowitz et al.		
	68.	02/09/2004	10/775,586	Rabinowitz et al.		
· · · · · · · · · · · · · · · · · · ·	69.	03/03/2004	10/791,915	Hale et al.		
	70.	03/03/2004	10/792,001	Rabinowitz et al.		
	71.	03/03/2004	10/792,012	Hale et al.		
	72.	03/03/2004	10/792,013	Rabinowitz et al.		
	73.	03/03/2004	10/792,096	Hale et al.		
	74.	03/03/2004	10/792,239	Hale et al.		
	75.	03/31/2004	10/813,721	Rabinowitz et al.		
	76.	03/31/2004	✓ 10/813,722 ✓	Rabinowitz et al.		
	77.	03/31/2004	√ 10/814,690 ∕	Rabinowitz et al.		
	78.	03/31/2004	√ 10/814,998 <i>/</i>	Rabinowitz et al.		
	79.	04/01/2004	. √10/815,527 /	Rabinowitz et al.		
	80.	04/01/2004	√ 10/816,407 ×	Rabinowitz et al.		
	81.	04/01/2004	10/816,492	Rabinowitz et al.		
	82.	04/01/2004	√10/816,567 /	Rabinowitz et al.		
	83.	08/04/2004	10/912,462	Hale et al.		
	84.	01/23/2003	US 2003/0015196	Hodges et al.		
	,		NO# EX	press Maicev 428 18940/101		
EXAN	MINER:		,	DATE CONSIDERED:		
				ation conforms with MPEP 609. Draw a line through the citation if not in h next communication to applicant.		

Form PTO-1449 Docket Number: 00037.09CON Application Number: 10/769,157 INFORMATION DISCLOSURE CITATION Applicant: Joshua D. RABINOWITZ et al. IN AN APPLICATION (Use several sheets if necessary) Group Art Unit: Not Yet Known Filing Date: 01/29/2004 85. l 04/03/2003 US 2003/0062042 Wensley et al. 86. 11/13/2003 US 2003/0209240 Hale et al. 87. 01/02/2003 US 2003/0000518 Rabinowitz et al. 01/09/2003 88. US 2003/0005924 Rabinowitz et al. US 2003/0005925 89. | 01/09/2003 Hale et al. 90. | 01/09/2003 US 2003/0007933 Rabinowitz et al. 91. 01/09/2003 US 2003/0007934 Rabinowitz et al. 92. 01/16/2003 US 2003/0012737 Rabinowitz et al. 93. 01/16/2003 US 2003/0012738 Rabinowitz et al. 94. 1/16/2003 US 2003/0012740 Rabinowitz et al. 95. 01/23/2003 US 2003/0015189 Rabinowitz et al. 01/23/2003 96. US 2003/0015190 Rabinowitz et al. 97. 01/23/2003 US-2003/0017114 Rabinowitz et al. 01/23/2003 98. US 2003/0017115 Rabinowitz et al. 99. 01/23/2003 US 2003/0017116 Rabinowitz et al. 01/23/2003 US 2003/0017117 100. Rabinowitz et al. 01/23/2003 101. US 2003/0017118 Rabinowitz et al. 01/23/2003 102. US 2003/0017119 Rabinowitz et al. 103. 01/23/2003 US 2003/0017120 Rabinowitz et al. 104. 1/30/2003 US 2003/0021753 Rabinowitz et al. 105. 01/30/2003 US 2003/0021754 Rabinowitz et al. 106. 01/30/2003 US 2003/0021755 Hale et al. 107. 02/20/2003 US 2003/0035776 Hodges et al. 108. 05/15/2003 US 2003/0091511 Rabinowitz et al. 109. 05/27/2004 US 2004/010148 Hale et al. 110. 07/31/2003 US 2003/0138382 Rabinowitz 111. 11/06/2003 US 2003/0206869 Rabinowitz et al. 112. 01/15/2004 US 2004/0009128. Rabinowitz et al. 113. 05/20/2004 US 2004/0096402 Hodges et al. 114. 05/27/2004 US 2004/0099269 Hale et al. DATE CONSIDERED: **EXAMINER:** EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PTO/SB/ 08 (2-92)

Sheet 5 of 8 Form PTO-1449 Docket Number: 00037.09CON Application Number: 10/769,157 Joshua D. RABINOWITZ et al. INFORMATION DISCLOSURE CITATION Applicant: IN AN APPLICATION (Use several sheets if necessary) Filing Date: 01/29/2004 Group Art Unit: Not Yet Known 06/03/2004 115. US 2004/0105818 Hale et al. 116. 06/03/2004 US 2004/0105819 Hale et al. 117. 07/01/2004 US 2004/0126326 Rabinowitz et al. 118. 07/01/2004 US 2004/0126327 Rabinowitz et al. 119. 07/01/2004 US 2004/0126328 Rabinowitz et al. 120. 07/01/2004 US 2004/0126329 Rabinowitz et al. 121. 07/01/2004 US 2004/0127481 Rabinowitz et al. 122. 07/01/2004 US 2004/0127490 Rabinowitz et al. 123. 08/12/2004 US 2004/0156788 Rabinowitz et al. 124. 08/12/2004 US 2004/0156789 Rabinowitz et al. 125. 8/12/2004 Rabinowitz et al. US 2004/0156790 126. 08/12/2004 US 2004/0156791 Rabinowitz et al. FOREIGN PATENT DOCUMENTS Examiner Ref. Date Document No. Country Class Subclass Translation **Initials** No. YES NO 127. 01/02/1996 CA 2,152,684 Canada 128. 03/14/1990 EP 0 358 114 Europe EP 1 080 720 129. 07/03/2001 Europe EP 0 606 486 130. 08/29/2001 Europe 131. 03/22/1990 WO 90/02737 **WIPO** 132. 04/11/1996 WO 96/09846 **WIPO** 133. 05/09/1996 WO 96/13161 **WIPO** 134. 05/09/1996 WO 96/13290 **WIPO** 135. 05/09/1996 WO 96/13291 **WIPO** 136. 05/09/1996 WO 96/13292 **WIPO** 137. 10/03/1996 WO 96/30068 **WIPO** 138. 08/07/1997 WO 97/27804 WIPO

DATE CONSIDERED: **EXAMINER:**

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number:	00037.09CON	Applicatio	n Number: 10/769,157		
INFOF		ON DISCLOST AN APPLICA	JRE CITATION FION	Applicant:	Joshua D.	RABINOWITZ	Cet al.
	(U	se several sheets if nec	essary)	Filing Date: 01/	/29/2004	Group Art	Unit: Not Yet Known
	1100	05/00/1000	WO 98/22170 ✓	/ / Lympo	·	I	
<u> </u>	139.	05/28/1998	11 0 30/22170	WIPO	•		
	140.	07/23/1998	WO 98/31346				
	141.	08/27/1998	WO 98/36651	WIPO	· · · · · · · · · · · · · · · · · · ·		
	142.	04/08/1999	WO 99/16419	WIPO			
	143.	12/16/1999	WO 99/64094	WIPO			
	144.	01/06/2000	WO 00/00176	WIPO			
	145.	01/06/2000	WO 00/00215	WIPO			
	146.	05/18/2000	WO 00/27363	WIPO			
	147.	05/25/2000	WO 00/29053	WIPO			
	148.	09/17/2000	WO 00/47203	WIPO			
~	149.	11/02/2000	WO 00/64940	WIPO			
	150.	11/09/2000	WO 00/66084	WIPO			
	151.	11/09/2000	WO 00/66206	WIPO			
	152.	12/21/2000	WO 00/76673	WIPO			
	153.	01/25/2001	WO 01/05459	WIPO			
	154.	03/28/2002	WO 02/24158	WIPO			
	155.	03/28/2002	WO 02/24158	WIPO			
		ОТНЕ	R DOCUMENTS	(including o	author, title, Date,	Pertinent Pages, E	ic.)
Examiner Initials	Ref. No.	Title	. •			,	
	156.		t al. (1981). "Patient-C Surg. 195(6):700-705		lgesia: A New	v Concept of P	ostoperative Pain
	157.		t al. (1990), "Cocaine-lopharmacology (Berl).		n rhesus mon	keys: reinforc	ing and physiological
	158.	Clark, A. and E Size," Z. Erkra	Byron, P. (1986). "Dependent. 166:13-24.	endence of Pul	monary Abso	orption Kinetic	s on Aerosol Particle
	159.	Darquenne, C. et al. (1997). "Aerosol Dispersion in Human Lung: Comparison Between Numerical Simulations and Experiments for Bolus Tests," <i>American Physiological Society</i> . 966-974.					
	160.	Davies, C.N. et al. (May 1972). "Breathing of Half-Micron Aerosols," Journal of Applied Physiology. 32(5):591-600.					
EXAMIN	VER:			DATE (CONSIDERED):	
			red, whether or not the citati			aw a line through	the citation if not in
PTO/SB/ 08 (ice; U.S. DEPAR'	TMENT OF COMMERCI

Form PTO-1449		Docket Number: 00037.09CON	Application Number: 10/769,157	
	ION DISCLOSURE CITATION AN APPLICATION	Applicant: Joshua D. RAB	INOWITZ et al.	
a	lse several sheets if necessary)	Filing Date: 01/29/2004	Group Art Unit: Not Yet Known	
161.	Dershwitz, M., M.D., et al. (Septembe versus Intravenous Morphine in Healt			
162.	Finlay, W.H. (2001). "The Mechanics Diego Formula 2.39. pp.3-14 (Table o		osols", Academic Press: San	
163.	Gonda, I. (1991). "Particle Deposition Scientific Foundations. Crystal R.G. a 2294.			
164.	Hatsukami D, et al. (May 1990) "A m humans." Pharmacology Biochemistry		es of smoked cocaine-base to	
165.	Heyder, J. et al. (1986). "Deposition o 0.005-15 μm," J. Aerosol Sci. 17(5):8		atory Tract in the Size Range	
166.	Huizer, H., "Analytical studies on illic Pharmaceutisch Weekblad Scientific L		ration during heroin smoking."	
167.	Hurt, R.D., MD and Robertson, C.R., Industry's Secrets About Nicotine: Th			
168.	Lichtman, A.H. et al. (1996). "Inhalati in Mice," Journal of Pharmacology an			
169.	Martin, B.R. and Lue, L.P. (May/June Analytical Toxicology 13:158-162.	1989). "Pyrolysis and Volatiliz	ation of Cocaine," Journal of	
170.	Mattox, A.J. and Carroll, M.E., (1996) Psychopharmacology, 125:195-201.). "Smoked heroin self-administ	ration in rhesus monkeys,"	
171.	McCORMICK, A.S.M., et al., "Bronc BRITISH JOURNAL OF ANAESTH			
172.	Meng, Y. et al. "Inhalation Studies Wi 173:201-224.	ith Drugs of Abuse, "NIDA Res	earch Monograph, (1997)	
173.	Meng, Y., et al. (1999). "Pharmacolog inhalation exposure," <i>Drug and Alcohology</i>		e and other stimulants via	
174.	Office Action mailed 8/13/2003 for US BENZODIAZEPINES THROUGH			
175.	Pankow, J.F. et al. (1997). "Conversio Free-Base Form Through the Action o			
176.	Pankow, J. (March 2000). ACS Confepp. 1-8.	rence-San Francisco-3/26/00. C	nemistry of Tobacco Smoke.	
177.	Seeman, J. et al. (1999). "The Form of Nicotine Acid Salts to Nicotine in the			
EXAMINER:		DATE CONSIDERED:		
	al if citation considered, whether or not the citation considered. Include a copy of this form with n		line through the citation if not in	
PTO/SB/ 08 (2-92)		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE		

PTO/SB/08 (2-92)

Form PTO	rm PTO-1449		Docket Number: 00037.09CON	Application Number: 10/769,157
INFOR		ON DISCLOSURE CITATION AN APPLICATION	Applicant: Joshua D. RAI	BINOWITZ et al.
	(U	se several sheets if necessary)	Filing Date: 01/29/2004	Group Art Unit: Not Yet Known
	178.	Sekine, H. and Nakahara, Y. (1987).	"Abuse of Smoking Methamphe	tamine Mixed with Tobacco: 1
		Inhalation Efficiency and Pyrolysis F 32(5):1271-1280.	Products of Methamphetamine,"	Journal of Forensic Science
·	179.	Vapotronics, Inc. (1998) located at ht June 5, 2000).		
	180.	Ward, M.E. MD, et al. (December 19 Administration from a Novel Aeroso 62(6):596-609.	97). "Morphine Pharmacokinetic I Delivery System," Clinical Pharmacokinetic	es after Pulmonary armacology & Therapeutics
	181.	Wood, R.W. et al. (1996). "Generation Pyrolyzate, Methylecgonidine, and E Biochemistry & Behavior. 55(2):237	Demonstration of Their Biologica	f Cocaine Base and Its al Activity." <i>Pharmacology</i>
		•		
			·	
		• •		
		•		
		·		
		•		
	NER:		DATE CONSIDERED:	· · · · · · · · · · · · · · · · · · ·